|
|
Welcome
Phacilitate’s 10th annual European Vaccine Forum will take place in Barcelona in May 2011. It will once again run in parallel to the Active Immunotherapeutics Forum – sharing some plenary sessions and all networking opportunities. All attendees will have access to all sessions during both programmes.
Comments from participants in the ’10 Barcelona meeting included:
"Very good science, interesting practical down to business debates, good networking"
Cristina Wilma, Director, Business Development/PreMarketing, Antisense Pharma GmbH
"This was an excellent meeting with lots of opportunity to network with key opinion leaders in the industry and make new contacts with potential clients"
David Kirke BSc (hons) MSc PhD CBiol MSB, Associate Director, ERA Consulting (UK) Ltd
"As a recent entrant to the sector, the event was very informative"
Ms Ann Kramer, COO, Immunocore Ltd
"Excellent networking opportunity as ever"
Dr Roeland van Dam, Manager, Corporate Development & Licensing, Netherlands Vaccine Institute
"As always, an extremely well organised conference, precisely the right size for effective networking"
Dr Kelly McKee, Vice President, Public Health & Government Services, Quintiles
"Very well organised, high quality speakers, tons of opportunities for interaction and networking amongst participants"
Dr Ioana R. Moldovan, Associate Director, GLP Laboratory, Cellular Technnology Limited (CTL)
|
The Barcelona Vaccine Forum provides an invaluable opportunity for leaders from across the vaccines sector to discuss their latest progress in overcoming core clinical, regulatory, manufacturing and business development challenges. The focus is mainly on prophylactic vaccines and related technologies, such as delivery systems and adjuvants. Detailed strategic analysis of global vaccine market opportunities, trends and challenges complete the programme.
|
The Active Immunotherapeutics Forum provides a unique annual meeting place for senior level figures driving the development of these technologies into clinically effective, cost-effective products that are acceptable to the regulator. Therapeutic vaccines against a variety of disease targets, as well as other immune modulating approaches, are covered, with the emphasis on how clinical, regulatory and manufacturing challenges are being overcome.
|
To contribute your views to the development of the programmes, please complete a Shape your Event form, or contact David McCall at david@phacilitate.co.uk (Tel: +44 (0)20 7839 6151).
©Copyright Phacilitate Limited 2010
|
Download the 2010 Main Agenda Announcement
|
